Philadelphia Chromosome Clinical Trials

1 recruiting

Philadelphia Chromosome Trials at a Glance

21 actively recruiting trials for philadelphia chromosome are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 14 trials, with the heaviest enrollment activity in Houston, Chicago, and Seattle. Lead sponsors running philadelphia chromosome studies include M.D. Anderson Cancer Center, Institute of Hematology & Blood Diseases Hospital, China, and University of Washington.

Browse philadelphia chromosome trials by phase

Treatments under study

About Philadelphia Chromosome Clinical Trials

Looking for clinical trials for Philadelphia Chromosome? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Philadelphia Chromosome trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Philadelphia Chromosome clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 21 trials

Recruiting
Phase 2

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRefractory B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)84 enrolled274 locationsNCT03739814
Recruiting
Phase 2

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Novartis Pharmaceuticals50 enrolled2 locationsNCT07354074
Recruiting
Phase 1

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

Advanced Chronic Myeloid LeukemiaPhiladelphia Chromosome-Positive Acute Myeloid Leukemia
M.D. Anderson Cancer Center30 enrolled1 locationNCT06401603
Recruiting
Phase 2

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeT Acute Lymphoblastic Leukemia
University of Washington30 enrolled1 locationNCT06738368
Recruiting
Phase 1

Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
H. Lee Moffitt Cancer Center and Research Institute36 enrolled1 locationNCT07250087
Recruiting
Phase 2

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Lymphoblastic LymphomaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
City of Hope Medical Center53 enrolled8 locationsNCT06918431
Recruiting
Phase 2

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
University of Washington30 enrolled1 locationNCT05453500
Recruiting
Phase 2

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center50 enrolled1 locationNCT01746836
Recruiting
Not Applicable

Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL

Philadelphia Chromosome Negative ALLAcute Lymphoblastic Leukemia, Adult
Institute of Hematology & Blood Diseases Hospital, China77 enrolled1 locationNCT06481241
Recruiting
Phase 2

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+5 more
M.D. Anderson Cancer Center90 enrolled1 locationNCT03263572
Recruiting
Phase 2

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Philadelphia Chromosome PositiveChronic Phase Chronic Myelogenous LeukemiaBCR-ABL1 Positive Chronic Myelogenous Leukemia+1 more
M.D. Anderson Cancer Center70 enrolled1 locationNCT05007873
Recruiting
Phase 1Phase 2

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

Recurrent Burkitt LymphomaRefractory Burkitt LymphomaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1+6 more
M.D. Anderson Cancer Center276 enrolled1 locationNCT01371630
Recruiting
Phase 2

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Acute Myeloid LeukemiaMyeloproliferative NeoplasmBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+4 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT03589729
Recruiting
Phase 1

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

B-cell Acute Lymphoblastic LeukemiaChronic Myeloid Leukemia (CML) in Lymphoid Blast CrisisPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
Marlise Luskin, MD40 enrolled4 locationsNCT03595917
Recruiting
Phase 2

Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients

Philadelphia Chromosome Negative ALLAcute Lymphobkastic LeukemiaAcute Lymphoblastic Leukaemia Recurrent
Hospital Universitario Dr. Jose E. Gonzalez12 enrolled1 locationNCT07039877
Recruiting
Phase 3

Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)Childhood Leukemia, Acute Lymphoblastic
Institute of Hematology & Blood Diseases Hospital, China150 enrolled24 locationsNCT07152041
Recruiting
Not Applicable

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

Philadelphia Chromosome Negative
University of Chicago20 enrolled1 locationNCT06785324
Recruiting
Phase 2

Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Goethe University220 enrolled85 locationsNCT06061094
Recruiting
Phase 3

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Chronic Myeloid Leukemia, Chronic PhaseCML, Chronic PhaseCML, Refractory+1 more
Il-Yang Pharm. Co., Ltd.173 enrolled18 locationsNCT03459534
Recruiting
Phase 2

Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

Philadelphia Chromosome PositiveAdult B Acute Lymphoblastic Leukemia
Brian Jonas20 enrolled1 locationNCT02997761